Development of Cyber Science Infrastructure (CSI)

DRFIC2008 Poster Session Recap one-minute oral presentation No.20DRFIC2008 ポスターセッションまとめ 口頭プレゼンテーション資料 20

Development of Cyber Science Infrastructure (CSI)

DRFIC2008 Poster Session No.20DRFIC2008 ポスターセッション資料 20

Two replications of "Hierarchical encoding makes individuals in a group seem more attractive (2014; Experiment 4)".

The cheerleader effect implies that a person in a group look like more attractive than in isolation. Walker and Vul (2014) reported results supporting the existence of the cheerleader effect. We replicated Walker and Vul’s Experiment 4, which manipulated group size. Their participants were asked to rate attractiveness of each female face image in a group (one of 4, 9, or 16 members) and in isolation and revealed that attractiveness ratings significantly increased in all the group conditions. We performed two direct replications of this experiment using Japanese participants. As a result, at least one experiment yielded a pattern of results similar to those of the previous study, although the effect was not significant and the effect size was small

Clinical outcomes of assisted reproductive technology treatment by using a self‐injection of recombinant human chorionic gonadotropin as the final maturation trigger

Abstract Purpose To evaluate the efficacy and safety of self‐injections of the prefilled recombinant human chorionic gonadotropin (r‐hCG) in a syringe in assisted reproductive technology (ART) treatment for the maturation trigger (MT), as compared to self‐injections of conventional hCG and intranasal administration of gonadotropin‐releasing hormone agonist (GnRH‐a). Methods Between January and April, 2017, 396 patients who underwent oocyte retrieval were recruited. Of these, 396 patients were classified into three groups, according to the types of MT: (1) the urinary human chorionic gonadotropin (u‐hCG) group that consisted of patients who had a self‐injection of u‐hCG (n = 127); (2) the GnRH‐a group that received nasal administration of GnRH‐a (n = 159); and (3) the r‐hCG group that had a self‐injection of r‐hCG (n = 110). Several ART outcomes were evaluated. Results The mature oocyte retrieval rate was not different between the u‐hCG, r‐hCG, and GnRH‐a groups and the fertilization and cleavage rates were similar between the three groups. The clinical pregnancy rates did not significantly differ between the GnRH‐a group and the u‐hCG group; however, it was significantly lower in the GnRH‐a group, compared to the r‐hCG group. No difference was observed in the incidence of moderate or more severe ovarian hyperstimulation syndrome among the three groups. Conclusion The self‐injection of the prefilled r‐hCG is a favorable MT for ART patients

Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF

Abstract Purpose Can relugolix, a novel oral gonadotropin‐releasing hormone receptor (GnRH) antagonist, function as an alternative ovulation inhibitor to GnRH antagonist injections? Methods This single‐center, cross‐sectional retrospective study compared premature ovulation rates and clinical outcomes in IVF treatment after mild ovarian stimulation with 40 mg of relugolix (relugolix group) or 0.25‐mg injections of ganirelix acetate or cetrorelix acetate (injection group) between March 2019 and January 2020. Of 247 infertile women (256 IVF cycles) aged ≤42 years, 223 women (230 cycles) were evaluated. In the relugolix and injection groups, we compared 104 and 85 cycles after GnRH antagonist use before the LH surge (LH levels <10 mIU/ml) and 22 and 19 cycles during the LH surge (LH levels ≥10 mIU/ml), respectively. Results Before the LH surge, the ovulation rates in the two groups were very low (p = 0.838), however; during the LH surge, the cycles using relugolix had a high ovulation rate of 40.9% compared with no ovulation in the injection group (p = 0.002). There were no significant differences in embryo culture findings and pregnancy outcomes between the two groups. Conclusions Although relugolix had a high ovulation suppressive effect, when the LH surge occurred, its effect was insufficient

Various pre-treatment factors and their correlation to pre-treatment NKG2D expression.

<p>Various pre-treatment factors and their correlation to pre-treatment NKG2D expression.</p

On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C

<div><p>Background and aims</p><p>Interferon (IFN)- free direct antiviral agents (DAAs) with rapid HCV eradication might evoke immunological reconstitutions, and some early recurrences of HCC after IFN-free DAAs have been reported. This study aimed to investigate whether natural killer group 2, member D (NKG2D) predicts early emergence of HCC after IFN-free DAAs.</p><p>Methods</p><p>We conducted a clinical practice-based observational study of 101 patients infected with genotype 1 HCV who received IFN-free (DAAs), and stratified them into those who did or did not develop early (i.e., during the 6-month surveillance period following treatment.) recurrence or occurrence of clinically evident HCC. We also analyzed the peripheral blood mononuclear cells, both before treatment and at end of treatment (EOT), of 24 of the patients who received IFN-free DAAs, and 16 who received IFN-combined protease inhibitor.</p><p>Results</p><p>We found early emergence of clinically evident HCC after IFN-free DAAs in 12 (12%) patients. Higher pre-treatment NKG2D expression, higher FIB-4 score, previous HCC history and failure to achieve sustained viral response were significant factors correlating to early HCC emergence. After IFN-free DAAs, a rapid decrease of NKG2D at EOT correlated with early HCC emergence in the IFN-free DAA-treated patients, but not in patients treated with the IFN-combined regimen. The decrease of NKG2D until EOT was predictive of early HCC emergence at a cut-off of -52% (AUC = 0.92).</p><p>Conclusions</p><p>On-treatment decrease of NKG2D may be a useful predictor of early emerging HCC in patients treated with IFN-free DAAs.</p></div

Pre- and End of Treatment NKG2D Expression of NK cells in IFN⁻/DAA-FU or IFN⁺ group.

<p>(a) Pre and EOT NKG2D expression of NK cells in each cases of IFN⁻/DAA-FU group. # represents cases with early-emerging HCC. (b, c) NKG2D Expression of NK cells in IFN⁻/DAA-FU group and in IFN⁺ group were compared between cases with or without early emergence of clinically evident HCC. Filled circles (pre) or triangles (EOT), cases with HCC; open circles (pre) or triangles (EOT), cases without HCC. Statistics were shown as median with interquartile ranges. *, <i>P</i>< 0.05; **, <i>P</i>< 0.01; NS, not significant.</p

On-treatment decreased of NKG2D correlated to early-emerging HCC.

<p>(a) Changes of NKG2D expression from pre to EOT (ΔNKG2D) were compared in the IFN⁻/DAA-FU group. The ROC analysis of ΔNKG2D and AFP at EOT as a predictive factor to early HCC emergence were shown. (B) Correlations of ΔNKG2D to other background characteristics and biochemical factors in the IFN⁻/DAA-FU group were shown. Y-axis: ΔNKG2D expression on NK cells. Filled circles (pre) or triangles (EOT), cases with HCC; open circles (pre) or triangles (EOT), cases without HCC. Statistics were shown as median with interquartile ranges. *, <i>P</i>< 0.05; **, <i>P</i>< 0.01.</p